Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens , including a platinum doublet , were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily ( E + T ) or erlotinib plus placebo ( E + P ) until disease progression .